NCT00688363

Brief Summary

The purpose of this randomized, prospective trial is to determine wether (a) a once weekly glucose profile (self monitoring) or (b) a three-monthly report of the actual glycated haemoglobin are effective interventions to improve HbA1c after one year in typ 2-diabetic patients on conventional insulin treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for phase_4 type-2-diabetes

Timeline
Completed

Started Feb 2003

Longer than P75 for phase_4 type-2-diabetes

Geographic Reach
1 country

41 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2003

Completed
5.3 years until next milestone

First Submitted

Initial submission to the registry

May 26, 2008

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 2, 2008

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2008

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2008

Completed
Last Updated

August 1, 2011

Status Verified

July 1, 2011

Enrollment Period

5.6 years

First QC Date

May 26, 2008

Last Update Submit

July 29, 2011

Conditions

Keywords

Diabetes controlglycated haemoglobinblood-glucose-self-monitoringtype 2-diabetesconventional insulin therapy

Outcome Measures

Primary Outcomes (1)

  • Haemoglobin A1c after one year

    1 year

Secondary Outcomes (7)

  • a representative blood glucose profile (self monitoring) during the week before the end of the trial

    1 year

  • body weight at the end of the trial

    1 year

  • serum, triglycerides and cholesterol (total HDL as well as LDL-cholesterol) at the end of the trial

    1 year

  • therapy-satisfaction (questionnaire)

    1 year

  • changes of the antidiabetic therapy

    1 year

  • +2 more secondary outcomes

Study Arms (4)

1

EXPERIMENTAL

No blood-glucose self-control, no HbA1c

Procedure: no blood-glucose self-control

2

EXPERIMENTAL

Blood-glucose self-control, no HbA1c

Procedure: weekly blood glucose profile

3

EXPERIMENTAL

No blood-glucose self-control, HbA1c

Procedure: three-monthly haemoglobin A1cProcedure: no blood-glucose self-control

4

EXPERIMENTAL

Blood-glucose self-control, HbA1c

Procedure: weekly blood glucose profileProcedure: three-monthly haemoglobin A1c

Interventions

once daily self-control of urinary-glucose

24

once daily self-control of urinary-glucose

34

once daily self-control of urinary-glucose

13

Eligibility Criteria

Age40 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Type 2-diabetes (ADA/WHO-Criteria)
  • Conventional insulin therapy ( 1-3 daily injections of basal- and/or mixed insulin also in combination with oral agents.)
  • Age:\> 40 years
  • BMI:\> 20 kg/m²

You may not qualify if:

  • Impaired liver function, defined as \> 2 times upper limit of normal
  • Impaired renal function defined liver enzymes as serum-creatinine \> 1.3 mg/dl
  • Gastro-intestinal diseases (disturbances, diagnoses)
  • Inability to perform study-related activities according to the present protocol
  • Pregnancy not certainly excluded
  • Abuse of alcohol and/or other drugs
  • Participation in other clinical trials during the past 3 month
  • Threat to general state of health
  • Intensified insulin therapy (at least 3 times rapid-acting insulin)
  • Frequent blood glucose self monitoring during the past 3 months (more than one 4-point glucose profile per week or more than one blood glucose/ urinary glucose test per day )

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (41)

Diabeteszentrum Bad Lauterberg

Bad Lauterberg im Harz, Lower Saxony, D-37431, Germany

Location

Koch, Peter

Bad Harzburg, 38667, Germany

Location

Maxeiner, Stefan

Bad Kreuznach, 55545, Germany

Location

Friedrichs, Michael

Bad Lauterberg im Harz, 37431, Germany

Location

Jödicke, Carmen

Bad Lauterberg im Harz, 37431, Germany

Location

Mulch-Wiemer, Christa

Bad Nauheim, 61231, Germany

Location

Bellmann, Renate

Berlin, 10365, Germany

Location

Schoch, Daniela

Berlin, 13055, Germany

Location

Warmers, Ulrike

Bitburg, 54634, Germany

Location

Leupold, Manfred

Borna, 04552, Germany

Location

Kamke, Wolfram

Burg/Sreewald, 03096, Germany

Location

Hildebrandt, Rüdiger

Clausthal-Zellerfeld, 38678, Germany

Location

Lemmerhirt, Jürgen

Cuxhaven, 27474, Germany

Location

Preuß, Uwe

Datteln, 45711, Germany

Location

Weller, Ulrich

Dorsten, 46282, Germany

Location

Fischer, Harald

Düren, 52351, Germany

Location

Krege, Peter

Emsdetten, 48282, Germany

Location

Gölz, Stefan

Esslingen am Neckar, 73728, Germany

Location

Wollersen, Karin

Freiburg im Breisgau, 79106, Germany

Location

Hendel, Andreas

Grassau, 83224, Germany

Location

Pfeiffer, Martha

Gronau, 48559, Germany

Location

Jäger, Michael

Höchst, 64739, Germany

Location

Müller, Ulrich. A.

Jena, 07740, Germany

Location

Niemetz, Ingo

Kassel, 34117, Germany

Location

Schmitz, Ulrike

Krefeld, 47805, Germany

Location

Kourbanova, Zarema

Langenfeld, 40764, Germany

Location

Willms, Gerhard

Leverkusen, 51373, Germany

Location

Ley, Heinz-Georg

Marl, 45770, Germany

Location

Grossmann, J.

Mönchengladbach, 41061, Germany

Location

Füchtenbusch, Martin

München, 80804, Germany

Location

Fueting, Frank

Nassau, 56377, Germany

Location

Behnke, Thomas

Neuwied, 56564, Germany

Location

Böhme, Rainer

Nordhausen, 99734, Germany

Location

Fels, Stefan

Oldenburg, 28131, Germany

Location

Klein, Frank

Schenklengsfeld, 36277, Germany

Location

Naumann, Rainer

Schöppenstedt, 38170, Germany

Location

Rieth-Kunert, Anna

Stade, 21684, Germany

Location

Nowack, Kirsten

Torgau, 04860, Germany

Location

Schmidt-Reinwald, Astrid

Waldrach, 54320, Germany

Location

Bödecker, A.-W.

Wiehl, 51674, Germany

Location

Oerter, Erika-Maria

Würzburg, 97084, Germany

Location

Related Publications (1)

  • Nauck MA, Haastert B, Trautner C, Muller UA, Nauck MA, Heinemann L; Clinical Trials Study Group of the German Association for the Study of Diabetes (Deutsche Diabetes-Gesellschaft). A randomised, controlled trial of self-monitoring of blood glucose in patients with type 2 diabetes receiving conventional insulin treatment. Diabetologia. 2014 May;57(5):868-77. doi: 10.1007/s00125-014-3168-1. Epub 2014 Jan 21.

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Michael A. Nauck, Prof. Dr.

    Diabeteszentrum Bad Lauterberg

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 26, 2008

First Posted

June 2, 2008

Study Start

February 1, 2003

Primary Completion

September 1, 2008

Study Completion

December 1, 2008

Last Updated

August 1, 2011

Record last verified: 2011-07

Locations